Selexis to expand its European operations

Swiss biotechnology company Selexis SA, which specializes in the creation of stable cell lines for the production of therapeutic proteins, says that it is to develop its manufacturing facilities and business operations. The firm added that it has already carried out expansion of its administrative offices and its manufacturing plant, the size of which has increased by 4,305 square feet.

Selexis said that, during 2006, its client base had grown 100%, and added that this included a record number of license renewals. The firm also said that further development of its facilities would enable it to provide the best possible service for its customers, and would form the basis for future corporate growth.

The company added that expansion would allow further improvement of its Sure Cell Line-based technology and associated services.